Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Agfa-Gevaert

DB:AGE
Snowflake Description

Moderate growth potential and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
AGE
DB
€571M
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

Agfa-Gevaert NV develops, produces, and distributes various analog and digital imaging systems, and IT solutions worldwide. The last earnings update was 20 days ago. More info.


Add to Portfolio Compare Print
  • Agfa-Gevaert has significant price volatility in the past 3 months.
AGE Share Price and Events
7 Day Returns
2.9%
DB:AGE
9.5%
DE Healthcare Services
9.9%
DE Market
1 Year Returns
-13.7%
DB:AGE
0.2%
DE Healthcare Services
-17.5%
DE Market
AGE Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Agfa-Gevaert (AGE) 2.9% -18.5% -31.1% -13.7% -29.7% 47.5%
DE Healthcare Services 9.5% -6.5% -16.6% 0.2% 27.1% 88.9%
DE Market 9.9% -16.6% -24.8% -17.5% -24.5% -28.1%
1 Year Return vs Industry and Market
  • AGE underperformed the Healthcare Services industry which returned 0.2% over the past year.
  • AGE outperformed the Market in Germany which returned -17.5% over the past year.
Price Volatility
AGE
Industry
5yr Volatility vs Market

AGE Value

 Is Agfa-Gevaert undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Agfa-Gevaert to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Agfa-Gevaert.

DB:AGE Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.3%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:AGE
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 6.2%
Healthcare Services Unlevered Beta Simply Wall St/ S&P Global 0.97
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.971 (1 + (1- 29%) (57.09%))
1.245
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.24
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.245 * 6.21%)
7.34%

Discounted Cash Flow Calculation for DB:AGE using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Agfa-Gevaert is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:AGE DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 7.34%)
2020 128.10 Est @ 53.24% 119.34
2021 175.68 Est @ 37.15% 152.48
2022 221.17 Est @ 25.89% 178.83
2023 260.98 Est @ 18% 196.60
2024 293.57 Est @ 12.49% 206.03
2025 318.89 Est @ 8.62% 208.49
2026 337.76 Est @ 5.92% 205.73
2027 351.36 Est @ 4.03% 199.38
2028 360.86 Est @ 2.7% 190.77
2029 367.26 Est @ 1.77% 180.88
Present value of next 10 years cash flows €1,838.00
DB:AGE DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= €367.26 × (1 + -0.39%) ÷ (7.34% – -0.39%)
€4,732.97
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €4,732.97 ÷ (1 + 7.34%)10
€2,331.03
DB:AGE Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €1,838.00 + €2,331.03
€4,169.03
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €4,169.03 / 167.75
€24.85
DB:AGE Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:AGE represents 0.9483x of ENXTBR:AGFB
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.9483x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (EUR) x Listing Adjustment Factor
= € 24.85 x 0.9483
€23.57
Value per share (EUR) From above. €23.57
Current discount Discount to share price of €3.23
= -1 x (€3.23 - €23.57) / €23.57
86.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Agfa-Gevaert is available for.
Intrinsic value
>50%
Share price is €3.23 vs Future cash flow value of €23.57
Current Discount Checks
For Agfa-Gevaert to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Agfa-Gevaert's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Agfa-Gevaert's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Agfa-Gevaert's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Agfa-Gevaert's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:AGE PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in EUR €-0.35
ENXTBR:AGFB Share Price ** ENXTBR (2020-03-31) in EUR €3.4
Germany Healthcare Services Industry PE Ratio Median Figure of 6 Publicly-Listed Healthcare Services Companies 11.39x
Germany Market PE Ratio Median Figure of 399 Publicly-Listed Companies 16.31x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Agfa-Gevaert.

DB:AGE PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTBR:AGFB Share Price ÷ EPS (both in EUR)

= 3.4 ÷ -0.35

-9.72x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Agfa-Gevaert is loss making, we can't compare its value to the DE Healthcare Services industry average.
  • Agfa-Gevaert is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Agfa-Gevaert's expected growth come at a high price?
Raw Data
DB:AGE PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -9.72x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
124.7%per year
Europe Healthcare Services Industry PEG Ratio Median Figure of 14 Publicly-Listed Healthcare Services Companies 2.3x
Germany Market PEG Ratio Median Figure of 255 Publicly-Listed Companies 1.18x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Agfa-Gevaert, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Agfa-Gevaert's assets?
Raw Data
DB:AGE PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in EUR €0.51
ENXTBR:AGFB Share Price * ENXTBR (2020-03-31) in EUR €3.4
Germany Healthcare Services Industry PB Ratio Median Figure of 7 Publicly-Listed Healthcare Services Companies 2.94x
Germany Market PB Ratio Median Figure of 571 Publicly-Listed Companies 1.43x
DB:AGE PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTBR:AGFB Share Price ÷ Book Value per Share (both in EUR)

= 3.4 ÷ 0.51

6.72x

* Primary Listing of Agfa-Gevaert.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Agfa-Gevaert is overvalued based on assets compared to the DE Healthcare Services industry average.
X
Value checks
We assess Agfa-Gevaert's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare Services industry average (and greater than 0)? (1 check)
  5. Agfa-Gevaert has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

AGE Future Performance

 How is Agfa-Gevaert expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
124.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Agfa-Gevaert expected to grow at an attractive rate?
  • Agfa-Gevaert's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Agfa-Gevaert's earnings growth is expected to exceed the Germany market average.
  • Agfa-Gevaert's revenues are expected to decrease over the next 1-3 years, this is below the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:AGE Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:AGE Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 124.7%
DB:AGE Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts -1.3%
Europe Healthcare Services Industry Earnings Growth Rate Market Cap Weighted Average 28.6%
Europe Healthcare Services Industry Revenue Growth Rate Market Cap Weighted Average 8.3%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.4%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:AGE Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:AGE Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 2,182 66 1
2020-12-31 2,197 25 1
2020-03-31
DB:AGE Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-12-31 2,239 123 -58
2019-09-30 2,268 31 -22
2019-06-30 2,254 -34 -23
2019-03-31 2,236 -17 -33
2018-12-31 2,247 -44 -24
2018-09-30 2,287 3 -3
2018-06-30 2,341 37 15
2018-03-31 2,404 9 36
2018-01-01 2,443 40 37
2017-09-30 2,467 77 46
2017-06-30 2,499 94 56
2017-03-31 2,522 141 68

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Agfa-Gevaert's earnings are expected to grow significantly at over 20% yearly.
  • Agfa-Gevaert's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:AGE Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Agfa-Gevaert Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:AGE Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 0.40 0.40 0.40 1.00
2020-12-31 0.15 0.15 0.15 1.00
2020-03-31
DB:AGE Past Financials Data
Date (Data in EUR Millions) EPS *
2019-12-31 -0.35
2019-09-30 -0.17
2019-06-30 -0.14
2019-03-31 -0.19
2018-12-31 -0.14
2018-09-30 -0.02
2018-06-30 0.09
2018-03-31 0.21
2018-01-01 0.22
2017-09-30 0.27
2017-06-30 0.33
2017-03-31 0.41

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Agfa-Gevaert will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Agfa-Gevaert's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Agfa-Gevaert has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

AGE Past Performance

  How has Agfa-Gevaert performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Agfa-Gevaert's growth in the last year to its industry (Healthcare Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Agfa-Gevaert does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Agfa-Gevaert's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Agfa-Gevaert's 1-year growth to the DE Healthcare Services industry average as it is not currently profitable.
Earnings and Revenue History
Agfa-Gevaert's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Agfa-Gevaert Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:AGE Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 2,239.00 -58.00 479.00 147.00
2019-09-30 2,268.00 -22.00 514.00 144.00
2019-06-30 2,254.00 -23.00 522.00 140.00
2019-03-31 2,236.00 -33.00 521.00 141.00
2018-12-31 2,247.00 -24.00 522.00 141.00
2018-09-30 2,287.00 -3.00 519.00 140.00
2018-06-30 2,341.00 15.00 521.00 143.00
2018-03-31 2,404.00 36.00 528.00 144.00
2018-01-01 2,443.00 37.00 532.00 144.00
2017-09-30 2,467.00 46.00 542.00 145.00
2017-06-30 2,499.00 56.00 545.00 145.00
2017-03-31 2,522.00 68.00 545.00 143.00
2016-12-31 2,537.00 70.00 543.00 141.00
2016-09-30 2,545.00 75.00 542.00 140.00
2016-06-30 2,581.00 83.00 542.00 141.00
2016-03-31 2,627.00 68.00 546.00 143.00
2015-12-31 2,646.00 62.00 551.00 144.00
2015-09-30 2,685.00 74.00 559.00 146.00
2015-06-30 2,660.00 50.00 557.00 147.00
2015-03-31 2,620.00 53.00 548.00 147.00
2014-12-31 2,620.00 50.00 544.00 146.00
2014-09-30 2,648.00 72.00 508.00 145.00
2014-06-30 2,701.00 58.00 556.00 143.00
2014-03-31 2,782.00 53.00 526.00 142.00
2013-12-31 2,865.00 41.00 581.00 146.00
2013-09-30 2,938.00 -19.00 552.00 146.00
2013-06-30 3,015.00 10.00 564.00 152.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Agfa-Gevaert has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Agfa-Gevaert has efficiently used its assets last year compared to the DE Healthcare Services industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Agfa-Gevaert improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Agfa-Gevaert's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Agfa-Gevaert has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

AGE Health

 How is Agfa-Gevaert's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Agfa-Gevaert's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Agfa-Gevaert is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Agfa-Gevaert's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Agfa-Gevaert's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 3.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Agfa-Gevaert Company Filings, last reported 3 months ago.

DB:AGE Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 130.00 326.00 107.00
2019-09-30 322.00 357.00 81.00
2019-06-30 318.00 396.00 85.00
2019-03-31 303.00 347.00 92.00
2018-12-31 290.00 285.00 141.00
2018-09-30 294.00 194.00 95.00
2018-06-30 306.00 144.00 89.00
2018-03-31 291.00 94.00 75.00
2018-01-01 307.00 86.00 68.00
2017-09-30 260.00 96.00 74.00
2017-06-30 260.00 98.00 71.00
2017-03-31 268.00 100.00 137.00
2016-12-31 252.00 111.00 129.00
2016-09-30 362.00 112.00 81.00
2016-06-30 338.00 125.00 73.00
2016-03-31 283.00 147.00 107.00
2015-12-31 268.00 181.00 123.00
2015-09-30 196.00 225.00 142.00
2015-06-30 182.00 233.00 131.00
2015-03-31 175.00 312.00 218.00
2014-12-31 146.00 322.00 196.00
2014-09-30 434.00 321.00 146.00
2014-06-30 411.00 334.00 158.00
2014-03-31 367.00 333.00 142.00
2013-12-31 368.00 343.00 126.00
2013-09-30 149.00 366.00 105.00
2013-06-30 154.00 426.00 127.00
  • Agfa-Gevaert's level of debt (250.8%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (220% vs 250.8% today).
  • Debt is well covered by operating cash flow (37.7%, greater than 20% of total debt).
  • Agfa-Gevaert is making a loss, therefore interest payments are not well covered by earnings.
X
Financial health checks
We assess Agfa-Gevaert's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Agfa-Gevaert has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

AGE Dividends

 What is Agfa-Gevaert's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Agfa-Gevaert dividends.
If you bought €2,000 of Agfa-Gevaert shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Agfa-Gevaert's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Agfa-Gevaert's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:AGE Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Healthcare Services Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 1.7%
Germany Market Average Dividend Yield Market Cap Weighted Average of 323 Stocks 3.8%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:AGE Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31
2020-03-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Agfa-Gevaert has not reported any payouts.
  • Unable to verify if Agfa-Gevaert's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Agfa-Gevaert's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Agfa-Gevaert has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Agfa-Gevaert's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Agfa-Gevaert afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Agfa-Gevaert has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

AGE Management

 What is the CEO of Agfa-Gevaert's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Pascal Juery
AGE 54
TENURE AS CEO 0 years
CEO Bio

Mr. Pascal Juéry serves as Chief Executive Officer at Agfa-Gevaert NV since February 1, 2020 and also serves as its President since 2020. Mr. Juéry provides extensive experience in the chemical and advanced material industries. Mr. Juéry started his career in finance and soon demonstrated his ability to lead various global businesses as well as hold key functional responsibilities. He was a member of the Executive Committee of Rhodia and then Solvay, where he took an active part in the group portfolio and business transformation. He is a graduate from ESCP Business School.

CEO Compensation
  • Insufficient data for Pascal to compare compensation growth.
  • Insufficient data for Pascal to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Agfa-Gevaert management team in years:

6.6
Average Tenure
55
Average Age
  • The average tenure for the Agfa-Gevaert management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Pascal Juery

TITLE
President & CEO
AGE
54

Dirk De Man

TITLE
Chief Financial Officer
TENURE
1.8 yrs

Wilfried Van Lishout

TITLE
Compliance Officer & Company Secretary
AGE
55

Viviane Dictus

TITLE
Director of Corporate Communications
TENURE
11.4 yrs

Stefaan Vanhooren

TITLE
President of Offset Solutions
AGE
55
TENURE
0.2 yrs

- Boyer

TITLE
Executive Vice President

Luc Delagaye

TITLE
President Digital Print & Chemicals and Radiology Solutions
AGE
59
TENURE
11.8 yrs

Luc Thijs

TITLE
President of Agfa Healthcare
AGE
54
Board of Directors Tenure

Average tenure and age of the Agfa-Gevaert board of directors in years:

1.8
Average Tenure
60
Average Age
  • The average tenure for the Agfa-Gevaert board of directors is less than 3 years, this suggests a new board.
Board of Directors

Klaus Röhrig

TITLE
Chairman of the Board
COMPENSATION
€25K
AGE
42
TENURE
0.8 yrs

Jo Cornu

TITLE
Independent Director
COMPENSATION
€70K
AGE
75
TENURE
18.2 yrs

Mark Pensaert

TITLE
Independent Director
COMPENSATION
€75K
AGE
55
TENURE
1.8 yrs

Christian Reinaudo

TITLE
Director
COMPENSATION
€2M
AGE
65
TENURE
10.2 yrs

Hilde Laga

TITLE
Independent Director
COMPENSATION
€70K
AGE
63
TENURE
4.8 yrs

Helen Routh

TITLE
Independent Director
AGE
57
TENURE
0.8 yrs

Frank Aranzana

TITLE
Independent Director
TENURE
0.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Agfa-Gevaert's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Agfa-Gevaert has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

AGE News

Simply Wall St News

AGE Company Info

Description

Agfa-Gevaert NV develops, produces, and distributes various analog and digital imaging systems, and IT solutions worldwide. The company operates through three segments: Agfa Graphics, Agfa HealthCare, and Agfa Specialty Products. The Agfa Graphics segment provides integrated prepress solutions, including computer to-plate systems and printing plates; and color management, workflow automation, and security design software for commercial, newspaper, and packaging printers. It also supplies a range of wide-format digital printing solutions to sign and display companies; offers print engines; and develops and manufactures inkjet inks and fluids for various industrial inkjet printing applications. The Agfa HealthCare segment provides diagnostic imaging and healthcare ray films, hardcopy film and printers, IT solutions for hospitals and care centers. It offers X-digital radiography equipment, and image processing software; picture archiving and communication systems, and radiology information systems; hospital information and clinical information systems; and integrated care solutions. The Agfa Specialty Products segment provides film-based products, such as films for non-destructive testing and aerial photography; and microfilms and films for the production of printed circuit boards. It also offers conductive polymers, materials for the production of high-security ID documents, membranes for hydrogen production, and synthetic papers. The company sells its products for use in the printing industry and healthcare sector; and for specific industrial applications through its own sales organization, as well as through a network of agents and representatives. Agfa-Gevaert NV was founded in 1867 and is headquartered in Mortsel, Belgium.

Details
Name: Agfa-Gevaert NV
AGE
Exchange: DB
Founded: 1867
€571,025,050
167,751,190
Website: http://www.agfa.com
Address: Agfa-Gevaert NV
Septestraat 27,
Mortsel,
Antwerp, 2640,
Belgium
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTBR AGFB Ordinary Shares Euronext Brussels BE EUR 01. Jun 1999
DB AGE Ordinary Shares Deutsche Boerse AG DE EUR 01. Jun 1999
LSE 0MFU Ordinary Shares London Stock Exchange GB EUR 01. Jun 1999
SWX AGFB Ordinary Shares SIX Swiss Exchange CH CHF 01. Jun 1999
BATS-CHIXE AGFBB Ordinary Shares BATS 'Chi-X Europe' GB EUR 01. Jun 1999
OTCPK AFGV.Y ADR Pink Sheets LLC US USD 16. Oct 2008
Number of employees
Current staff
Staff numbers
9,662
Agfa-Gevaert employees.
Industry
Health Care Technology
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/31 20:39
End of day share price update: 2020/03/31 00:00
Last estimates confirmation: 2020/03/11
Last earnings filing: 2020/03/11
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.